Novo Nordisk(US:NVO) Xin Hua Cai Jing·2025-07-30 00:54Core Viewpoint - The Danish pharmaceutical company Novo Nordisk has issued a profit warning, significantly lowering its sales and operating profit growth expectations for 2025 due to disappointing sales performance of its flagship weight loss drug Wegovy, leading to a sharp decline in its stock price [4]. Group 1: Company Performance - Novo Nordisk's stock price fell over 21% as of the market close on July 29 [2]. - The company revised its sales growth forecast from 13%-21% to 8%-14% and its operating profit growth forecast from 16%-24% to 10%-16% [4]. - The disappointing performance of Wegovy is attributed to lower-than-expected penetration in cash payment channels and ongoing competition from generic drugs [4]. Group 2: Market Competition - Wegovy, known for its weight loss capabilities, faces increased competition from Eli Lilly's similar product, tirzepatide, which acts on both GLP-1 and GIP receptors, potentially offering better weight loss and glucose-lowering effects [5]. - Several domestic pharmaceutical companies are also developing generic versions of semaglutide, with companies like Huadong Medicine, Lizhu Group, Qilu Pharmaceutical, and United Pharmaceutical already in the process of product registration [5]. Group 3: Management Changes - Novo Nordisk announced the appointment of Maziar Mike Doustdar as the new President and CEO, effective August 7 [4].